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ABSTRACT
Objective: Cancer is the major worldwide problem. It arises due to uncontrolled growth of cells. In the present study, a series of novel coumarin 
derivatives were designed and computationally optimized to investigate the interaction between designed ligands and 10 protein data bank (pdb) 
files of five selected proteins. The objective here was to analyze in silico anticancerous activity of designed ligands to reduce cost and time for getting 
the novel anticancerous drug with minimum side effects.
Methods: Docking studies were performed to find out the maximum interaction between designed ligands and selected five proteins using 
Schrodinger software Maestro. Capecitabine has been used as reference compound. Structures of selected proteins were downloaded from protein 
data bank.
Results: All the designed ligands showed mild to excellent binding with proteins. Most of the ligands exhibited better interaction compared to 
reference compound capecitabine with all pdb files. Some of the designed ligands among (1-7) showed excellent docking score with all pdb files 
(2v5z, 2v60, 2v61) of amine oxidase.
Conclusion: All the designed ligands were docked with 10 pdb files of five different proteins, and it was found that out of seven designed ligand, 
ligand 4 showed the best binding (docking score −10.139) with pdb 2v5z of protein amine oxidase. Docked ligand cavity of ligand 4 showed important 
hydrophobic/non-polar residues such as Ile199, Ile316, Trp119, Phe168, Ile198, Cys172, Tyr188, Tyr398, Tyr435, Phe343, Tyr60, Leu328, Leu171, 
and showed pi-pi interaction with Tyr326. Further wet laboratory studies are continued in our laboratory to confirm and find out efficiency and 
activity of target compounds.
Keywords: Docking, Monoamine oxidase, Coumarin derivatives, Anticancerous activity, Binding energy, Ramachandran plot, Hydrophobic residue.
INTRODUCTION
In spite of the development of many cancer drugs in recent years [1], 
cancer is considered the major threat for human health [2]. Coumarin 
is one of the most widespread scaffolds in medicinal chemistry, and its 
derivatives are reported to possess anticancerous property [3] along 
with other biological activities [4,5].
Monoamine oxidases (MAOs) are flavin adenine dinucleotides 
containing an enzyme which are tightly bound to the outer membranes 
of mitochondria through a cysteine residue that catalyzes the 
degradation of monoamine neurotransmitters and dietary amines 
by oxidative deamination, which produces a by-product, hydrogen 
peroxide, a major source of reactive oxygen species [6]. There was 
significant correlation found between increased levels of MAOA 
expression and high Gleason grade or poorly differentiated human 
prostate tumors [7]. Coumarin derivatives have been recognized 
as potential MAO inhibitors [8]. It is a cytosolic reductase and is up-
regulated in many human cancers compared to adjacent normal 
tissues [9]. Dicoumarol and series of 4-hydroxycoumarin derivatives 
have been reported to inhibit overexpressed NAD(P)H dehydrogenase 
(quinone) 1 (NQO1) in many cancer cells [10]. Epidermal growth 
factor receptor (EGFR), a member of ERBb family of tyrosine kinase of 
Rtk and, is associated with pathogenesis and development of different 
types of cancers [11,12].
Coumarin derivatives like Daphnetin have been identified as EGFR-
PTK inhibitors [13]. The enzyme cytochrome P450 2A6 (CYP2A6) is 
a key factor in genesis and treatment of breast cancer cells [14] and 
lung cancer [15]. P450 2A6 activate procarcinogens and also play a 
major role in the inactivation and activation of anticancer drugs [16]. 
Binding of P450 2A6 with coumarin and methoxsalen are also reported 
in literature [17]. Protein kinase C (PKC) has proved an interactable 
target in cancer therapeutics [18]. PKC a prototypical class of enzyme 
which gives signals the molecules that are linked with multiple 
cellular processes of cancer. Furo-coumarinsulfonamides acts as PKC 
inhibitors particularly for cancer tumors [19]. Anticancerous drugs 
in the market are reported to have cytotoxic properties, coumarin 
compounds having antioxidant and cytostatic properties so it can 
minimize side effects caused due to existing drugs, radiotherapy and 
surgery [20]. Neo-tanshinlactone a coumarin-containing compound is 
reported to have better selectivity and potency than tamoxifen [21]. 
These valid information from literature showing the involvement of 
selected proteins in genesis of cancer and their binding affinity with 
coumarin derivatives prompted authors to design novel coumarin 
derivatives.
Molecular docking study is a well-established technique to determine 
the interaction of two molecules. This technique evolves the best 
orientation of ligand and protein forming a complex with minimum 
energy [22,23]. Typically, it is used in the process of developing new 
drugs and identifies proteins responsible for the appearance or 
progression of disease in the body. The designed novel coumarin-based 
ligands, 1-7 have been subjected for studying binding interactions with 
five receptors. In the present study, novel coumarin derivatives were 
analyzed for their in silico anticancer activity against 10 protein data 
bank (pdb) files of five proteins, namely, amine oxidase, NQO1, EGFR, 
CYP2A6, and protein kinase and their docking scores were compared 
with the reference compound capecitabine by computational docking 
protocol.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16826
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METHODS
Ligand preparation
Three-dimensional (3D) structures of all atoms in molecules can be 
generated using LigPrep. While preparing ligands for molecular docking 
two-dimensional (2D) structures are converted into 3D structures for 
generating variations, correction, verification, and optimization of the 
structures. While binding with ligands receptors adopts more than one 
conformation. Ligands of novel coumarin derivatives were designed by 
substituting 3rd, 5th, 6th, 7th, and 8th position of coumarin nucleus. 5th, 6th, 
7th, and 8th positions were substituted with hydroxyl, acetoxy, iodine, 
and -CF3 group, respectively. The third position of coumarin nucleus 
was substituted with phenyl group.
A general structure of designed ligands (Prototype 1) and reference 
compound is mentioned in Fig. 1, substituents of designed ligands with 
their IUPAC names are mentioned in Table 1.
Protein preparation
A molecular library of seven compounds (Ligand 1-7 along with 
reference compound) was docked with the five proteins for anticancer 
activity. Pdb files of all proteins viz. 2qc6, 1m17, 2pwb, 2v5z, 2v60, 
2v61, 2ya3,4rui, 2f10, 3jsx were downloaded from PDB (www.rcsb. rg), 
having resolution of 2.20 Å. Ramachandran plot of pdb files (2v5z, 2v60, 
2v61, and 2qc6) of proteins amine oxidase and protein kinase showing 
the best result with designed ligands are mentioned in Fig. 2.
Grid generation
The best interaction between one or more ligands and receptor 
molecules can be studied with Glide search. The receptor grid can be 
set up and generated from the receptor grid generation panel. Without 
generating receptor grid, ligand cannot be docked with receptors. In 
this study, OPLS_2005 force field was used for generating grid.
Molecular docking
Docking studies of ligands and proteins [24] were performed to 
determine anticancer activity [25,26]. The selected ligands and proteins 
were docked using Schrodinger software. The docking program 
evaluated energies to obtain the best binding mode. The docking score of 
all designed ligands, reference compound with proteins amine oxidase, 
NQO1, EGFR, protein P450, and protein kinase are mentioned in Table 2.
Hydrogen bond interaction
The amino acids of the protein interact with set of designed ligands and 
contribute the main role in their binding. The higher affinity of these 
Fig. 1: Structure of prototype-1 of docked ligands and reference 
compound
Table 1: Substituentsof designed ligands with their IUPAC name
Ligands R1 R2 R3 R4 R5 IUPAC name
1 -H -H -H -H -H 2H-Chromene-2-one
2 -H -OH -H -OH -H 5,7-dihydroxy-2H-chromene-2-one
3 -C6H5 -OH -H -OH -H 5,7-dihydroxy-3-phenyl-2H-chromen-2-one
4 -C6H5 -OH -H -OAc -H 5.hydroxy-2-oxo-3-phenyl-2H-chromen-7-yl acetate
5 -C6H5 -OAc -H -OAc -H 2-oxo-3-phenyl-2H-chromen-5,7-diyl diacetate
6 -C6H5 -OH -I -OH -I 5,7-dihydroxy-6,8-diiodo-3-phenyl-2H-chromen-2-one
7 -C6H5 -OH -CF3 -OAc -CF3 5-hydroxy-2-oxo-3-phenyl-6,8-bis (trifluoromethyl)-2H-chromen-7-yl acetate
Table 2: Docking scores of ligand 1-7 and reference compound with protein amine oxidase, NQO1, EGFR, protein P450 and protein 
kinase




Glide H-bond Glide evdw Glide ecoul Glide 
energy
1 Amine oxidase 2v5z 1 44.618 −7.962 −0.32 −27.558 −3.521 −31.08
2 46.504 −8.208 −0.32 −31.369 −4.743 −36.112
3 83.703 −9.557 −0.207 −40.27 −2.148 −42.418
4 97.89 −10.139 −0.383 −41.538 −6.179 −47.718
5 109.183 −9.424 −0.48 −29.871 −4.577 −34.448
6 92.219 −8.034 −0.135 −42.258 −0.111 −42.369
7 134.675 −9.445 −0.32 −15.991 −6.426 −22.416
*8 137.019 −8.207 −0.035 −46.884 −3.643 −50.527
2v60 1 44.618 −7.142 −0.013 −25.353 −1.964 −27.317
2 46.504 −7.406 −0.193 −23.5 −6.554 −30.054
3 83.703 −8.38 −0.302 −30.326 −4.297 −34.623
4 97.89 −8.072 0 −33.963 0.224 −33.739
6 92.219 −6.628 −0.32 −18.655 −2.136 −20.791
8 137.019 −6.074 −0.24 −21.161 −2.729 −23.89
2v61 1 44.618 −7.318 0 −27.056 −1.239 −28.295
2 46.504 −7.244 0 −29.612 −2.966 −32.579
3 83.703 −8.818 −0.035 −28.166 −1.071 −29.237
4 97.89 −9.112 −0.147 −29.856 −1.755 −31.611
5 109.183 −4.597 −0.509 −39.437 −4.63 −44.067
6 84.463 −8.151 −0.481 −29.344 −8.859 −38.203
*8 137.019 −7.383 −0.346 −18.918 −6.032 −24.95
*8: Reference compound – Capecitabin. NQO1: NAD (P) H dehydrogenase [quinone] 1, EGFR: Epidermal growth factor receptor
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ligands to proteins was primarily due to the formation of hydrogen bonds. 
Number of hydrogen bonds provides stability to ligand-protein complex. 
Hydrogen bonding among amino acids of selected pdb files of proteins 
and ligand molecules, having docking score <−8.00 are given in Table 3.
RESULTS AND DISCUSSION
Docking simulation technique revealed very interesting results for 
library of designed ligands. Results indicated that binding of all 
designed ligands showed docking scores with 3 pdb files 2v5z, 2v60, 
2v61 of amine oxidase ranging from (−7.962 to −10.139), (−7.142 to 
−8.38), (−4.597 to −8.818), and binding energies ranging from (−22.416 
to −47.718), (−20.791 to −34.623), (−23.89 to −44.067), respectively. 
Details of docking score and docking energies of ligands (1-7) and 
reference compound 8 with pdb files 2v5z, 2v60, 2v61 of selected 
amine oxidase protein is mentioned in Table 2.
Graphical representation of docking score and docking energies of 
ligands 1-7 and reference compound 8 with pdb files of all selected 
proteins are well defined in Figs. 3a and b.
These ligands were also analyzed for their potential energy-OPLS-2005, 
glide H-bond, glide evdw, and glide ecoul values. For all ligands 
OPLS-2005 values were ranging from −20.791 to −47.718, values of 
glide H-bond were found to be in the range of 0 to −0.481, values of glide 
evdw were ranging from −15.991 to −46.884, and values of glide ecoul 
were ranging from −0.111 to −8.859. Standard values for glide evdw and 
ecoul should be <100 and glide H-bond it should be <−0.05 (Table 2).
These ligands were also studied for their hydrophobic interactions with 
selected pdb files having docking score ≤−8.00. It was analyzed that 
all seven ligand showed hydrophobic interactions with four pdb files 
2v5z, 2v60, and 2v61 in 11 different ways. The analysis of hydrophobic 
interactions of ligands 2, 3, 4, 5, 6, 7 with pdb file 2v5z of protein amine 
oxidase are discussed herewith, namely, with ligand 2 residues were 
found to be Leu171, Tyr326, Phe343, Tyr60, Tyr435, Cys172, Ile198, 
Ile199, ligand 3 involved important hydrophobic/non-polar residues 
such as Phe168, Ile199, Leu171, Tyr326, Phe343, Leu328, Tyr60, 
Met341, Tyr435, Cys172, ligand 4 involved important hydrophobic/
non-polar residues such as Ile199, Ile316, Trp119, Phe168, Ile198, 
Cys172, Tyr188, Tyr398, Tyr435, Phe343, Tyr60, Leu328, Leu171, 
and π-π interactions with Trp326, ligand 5 involved important 
hydrophobic/non-polar residues such as Ile198, Ile199, Ile316, 
Leu167, Leu168, Leu328, Leu171, Met341, Phe168, Phe343, Pro102, 
Pro104, Trp119, Tyr326, Tyr398, Tyr435, Tyr60, ligand 6 involved 
important hydrophobic/non-polar residues such as Cyr188, Cys172, 
Ile198, Ile199, Ile316, Leu164, Leu167, Leu328, Leu171, Phe168, 
Phe343, Pro102, Pro104, Tyr326, Trp119, Tyr398, Tyr435, Tyr60, and 
docked ligand 7 involved important hydrophobic/non-polar residues 
such Cys172, Ile198, Ile199, Ile316, Leu167, Leu328, Leu171, Phe168, 
Phe343, Tyr326, Trp119, Tyr398, Tyr435, Tyr60.
Similarly, ligand 3 and 4 showed hydrophobic interactions with pdb 
file 2v60 of amine oxidase. Wherein ligand 3 involved important 
hydrophobic/non-polar residues such as Ile316, Phe103, Leu164, 
Trp119, Phe168, Leu167, Cys172, Ile198, Tyr188, Tyr398, Tyr435, 
Phe343, Leu1171, Tyr326, Ile199, Phe99, Pro104 and ligand 4 involved 
important hydrophobic/non-polar residues such as Cys172, Ile198, 
Ile199, Ile316, Leu164, Leu167, Leu171, Met341, Phe168, Phe103, 
Pro102, Pro104, Phe343, Tyr60, Tyr398, Leu171 and π-π interactions 
with Trp119, Tyr326.
Three ligands, i.e., 3, 4, 6were showing hydrophobic interactions with 
pdb file 2v61 of amine oxidase wherein ligand 3 involved important 
hydrophobic/non-polar residues such as Trp119, Pro104, Ile316, 
Pro102, Ile199, Leu328, Tyr60, Phe343, Tyr435, Ile198, Leu171, Cys172, 
Phe168, Leu167, Ile164, Trp119, and π-π interactions with Tyr326, 
ligand 4 involved important hydrophobic/non-polar residues such as Fig. 2: Ramachandran plot of pdb files (2v5z, 2v60, 2v61)
Table 3: Receptor interactions within 4 Å for best ligands




2 Tyr435, Tyr396, Tyr188, Tyr326, Phe343, Tyr60, Cys172, Ile198, Ile199 Gln206 -
3 Phe168, Ile199, Leu171, Tyr326, Phe343, Leu328, Tyr60, Met341, Tyr435, 
Cys172, Ile198
Gln206 -
4 Ile199, Ile316, Trp119, Phe168, Ile198, Cys172, Tyr188, Tyr398, Tyr435, 
Phe343, Tyr60, Leu328, Leu171
Gln206 Tyr326
5 - Ile198, Ile199, Ile316, Leu167, Leu168, Leu328, Leu171, Met341, Phe168, 
Phe343, Pro102, Pro104, Trp119, Tyr326, Tyr398, Tyr435, Tyr60
Gln206
6 - Cyr188, Cys172, Ile198, Ile199, Ile316, Leu164, Leu167, Leu328, Leu171, 
Phe168, Phe343, Pro102, Pro104, Tyr326, Trp119, Tyr398, Tyr435, Tyr60
Gln206 -
7 - Cys172, Ile198, Ile199, Ile316, Leu167, Leu328, Leu171, Phe168, Phe343, 
Tyr326, Trp119, Tyr398, Tyr435, Tyr60
Gln206 -
2v60
3 Pro102 Ile316, Phe103, Leu164, Trp119, Phe168, Leu167, Cys172, Ile198, Tyr188, 
Tyr398, Tyr435, Phe343, Leu1171, Tyr326, Ile199, Phe99, Pro104
Gln206 -
4 - Cys172, Ile198, Ile199, Ile316, Leu164, Leu167, Leu171, Met341, Phe168, 
Phe103, Pro102, Pro104, Phe343, Tyr60, Tyr398
Gln206 Trp119, Tyr326
2v61
3 Trp119, Pro104, Ile316, Pro102, Ile199, Leu328, Tyr60, Phe343, Tyr435, 
Ile198, Leu171, Cys172, Phe168, Leu167, Ile164, Trp119
- Tyr326
4 - Cys172, Ile198, Ile199, Ile316, Leu164, Leu167, Leu328, Leu171, Phe103, 
Phe168, Phe343, Pro102, Pro104, Tyr60,Tyr398
Gln206 Trp119, Tyr326
6 Ile316, Pro104, Leu164, Trp119, Leu167, Phe168, Leu171, Tyr188, Ile198, 
Cys172, Tyr435, Tyr398, Phe343, Tyr60, Leu328, Tyr326, Ile199, Pro102
Gln206 -
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Cys172, Ile198, Ile199, Ile316, Leu164, Leu167, Leu328, Leu171, Phe103, 
Phe168, Phe343, Pro102, Pro104, Tyr60, Tyr398, and π-π interactions 
with Trp119, Tyr326, and ligand 6 involved important hydrophobic/non-
polar residues such as Ile316, Pro104, Leu164, Trp119, Leu167, Phe168, 
Leu171, Tyr188, Ile198, Cys172, Tyr435, Tyr398, Phe343, Tyr60, Leu328, 
Tyr326, Ile199, Pro102 with no π-π interactions.
All the docked ligands 1-7 involved important polar residues Gln206. 
Details of hydrophobic interactions of above-mentioned ligands are 
given in Table 3. 2D and 3D representation of all ligands showing 
hydrophobic interactions in pictorial form are mentioned in Figs. 4-15.
CONCLUSION
The aim of the present study was to find out inhibitor ligands for 5 selected 
proteins, i.e., amine oxidase, NQO1, EGFR, P450, and protein kinase, which 
could interfere at molecular level to reduce expression of these proteins to 
control and prevent cancer. Docking studies were performed for unknown 
coumarin derivatives (ligands 3-7) and for coumarin congeners (ligands 
1-2, possible precursors of ligands 1-7) for a better understanding of 
docking studies using Schrodinger software. Docking studies included 
calculation of docking score, docking energy, ecoul, H-bond, evdw and 
hydrophobic interaction of these ligand with selected proteins. Based on 
docking studies it was found that all ligands showed excellent binding 
with 3 pdb files (2v5z, 2v60 and 2v61) of amine oxidase. They showed 
mild to moderate binding with all pdb files of proteins; averagely these 
ligands showed better binding than reference compound capecitabine.
Fig. 10: Hydrophobic interaction of ligand 3 with 2v60 
two-dimensional (a) and three- dimensional (b)
Fig. 3: (a and b) Docking score and docking energy of ligands 
1-7 and reference compound 8 with pdb files (2v5z, 2v60, 2v61) 
of protein amine oxidase
a b
Fig. 4: Hydrophobic interaction of ligand 2 with 2v5z 
two-dimension (a) and three-dimensional (b)
a b
Fig. 5: Hydrophobic interaction of ligand 3 with 2v5z 
two-dimensional (a) and three-dimensional (b)
a b
Fig. 6: Hydrophobic interaction of ligand 4 with 2v5z 
two-dimensional (a) and three-dimensional (b)
a b a b
Fig. 9: Hydrophobic interaction of ligand 7 with 2v5z 
two-dimensional (a) and three- dimensional (b)
a b
Fig. 8: Hydrophobic interaction of ligand 6 with 2v5z 
two-dimensional (a) and three-dimensional (b)
a b
Fig. 7: Hydrophobic Interaction of ligand 5 with 2v5z 
two-dimensional (a) and three-dimensional (b)
a b
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Upon visualization of results of docking studies in the form of Glide 
docking scores from the library of designed ligands (2-7), it was found 
ligands (2-7) showed docking scores (−8.034 to −10.139) and docking 
energy (−31.08 to −50.527) for pdb files 2v5z of amine oxidase. 
Similarly, for pdb 2v60 of amine oxidase ligands 3 and 4 showed docking 
scores (−8.072 and −8.38), docking energies (−33.739 and −34.623) 
respectively. Likewise for pdb file 2v61 of amine oxidase, ligands 3, 4 
and 6 showed docking scores (−8.818, −9.112 and −8.151) and docking 
energies (−29.237, −31.611 and −38.203) respectively. It can also be 
inferred that above-mentioned ligands showing docking score <−8.00 
exhibited excellent hydrophobic interactions with proteins. They are 
also well in a range of six parameters for calculation of G score.
Therefore, we conclude that above mentioned 11 interactions of 
ligands (2-7) with three pdb files of protein amine oxidase and one pdb file 
of protein kinase are giving very exciting results, it was also found that ligand 
4 was showing excellent docking score, i.e., (−10) including all parameters 
of G score, with pdb file (2v5z) of amine oxidase. Hence, ligands (2-7), 
with a particular focus on ligand 4 can be developed as the excellent lead 
for a potential inhibitor of amine oxidase for their anticancerous activity. 
Authors wanted to generate these compounds as novel anticancerous drug, 
as coumarin derivatives are associated with antioxidant properties and 
with minimum side effects. Further wet laboratory studies are continued 
in our laboratory to confirm the properties of these ligands molecules.
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